ROCHESTER—Officials at OptimizeRx Corp. (NASDAQ: OPRX), a provider of digital health messaging in the pharmaceutical industry, announced the appointment of Stephen Silvestro to the new position of chief commercial officer.
Silvestro will be responsible for driving OptimizeRx’s platform revenue growth, including enterprise level direct-to-patient and direct-to-provider product adoption to improve patient outcomes.
OptimizeRx CEO Will Febbo praised Silvestro’s “important experience, depth of knowledge and a shared determination to provide affordability and adherence solutions that link the health care and life sciences industries. During his tenure at Decision Resources Group, he was an instrumental leader in the growth of the company from $30 million to $180 million in revenue. His customer-first philosophy is greatly aligned to our values at OptimizeRx. We are confident in the market appetite for our solutions. We believe Steve will drive incredible growth with our core clients and take the company to the next level in terms of reach, revenue and earnings.”
OptimizeRx is the largest point-of-care network in the United States, reaching more than half the ambulatory market. Through their digital health platform, pharma companies have critical access to doctors and their patients to provide medication information and savings. The acquisition of CareSpeak and announcement of expansion into health and hospital systems reflect technology capabilities to deliver savings and adherence messages throughout the entire care continuum.
Silvestro commented: “It’s an exciting time to join the OptimizeRx team. We see a sustained growth opportunity for the business driven by strong industry momentum to improve connections between pharma, healthcare providers and patients. There is ample room to grow with more than $1 billion of total addressable market. This opportunity is amplified by the more than $528 billion non-adherence impact which simply isn’t acceptable. I’m passionate about improving outcomes for patients, and OptimizeRx provides a unique vehicle to help. I’m excited to help lead the organization through its next phase of growth and to bring some of the best practices and strong commercial discipline from my years of building and leading best in class commercial organizations.”
Silvestro previously served as vice president and general manager at CCH Tagetik, a division of Wolters Kluwer. Prior pharma leadership experience includes executive positions with Prognos, Decision Resources Group and D.M.S. Silvestro has extensive channel expertise in biopharma commercialization, global market access, market research, analytics, enterprise SaaS solutions and strategy.
Silvestro received a master’s degree in business management from Harvard University. He also holds undergraduate degrees from Brigham Young University in both business and Italian. He is fluent in English, Italian, Spanish and conversational in French. He will be based in Boston, Mass.
For more information on OptimizeRx, visit OptimizeRx.com.
OptimizeRx connects pharmaceutical companies to patients and providers, offering greater affordability, adherence and brand awareness at the point-of-care. OptimizeRx provides a direct channel for pharma companies to communicate with healthcare providers right within their workflow and also directly to patients. The cloud-based system supports patient adherence to medications and better healthcare outcomes with real-time access to financial assistance, prior authorization, education and critical clinical information. OptimizeRx provides more than half of the ambulatory patient market with access to these benefits through leading EHR platforms like Allscripts, Amazing Charts and Quest, and directly via its mobile communications platform.